Hims & Hers Health, Inc. (NYSE:HIMS) Shares Sold by Institutional Venture Management XVI LLC

Institutional Venture Management XVI LLC cut its holdings in Hims & Hers Health, Inc. (NYSE:HIMS) by 32.4% during the 1st quarter, Holdings Channel reports. The firm owned 5,222,570 shares of the company’s stock after selling 2,500,000 shares during the period. Hims & Hers Health comprises approximately 93.9% of Institutional Venture Management XVI LLC’s investment portfolio, making the stock its biggest holding. Institutional Venture Management XVI LLC’s holdings in Hims & Hers Health were worth $80,793,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also modified their holdings of the company. Vanguard Group Inc. boosted its stake in shares of Hims & Hers Health by 1.0% during the 1st quarter. Vanguard Group Inc. now owns 14,310,192 shares of the company’s stock worth $221,379,000 after purchasing an additional 136,907 shares during the last quarter. Forerunner Ventures Management LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth approximately $86,836,000. Dimensional Fund Advisors LP raised its holdings in Hims & Hers Health by 9.9% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,147,927 shares of the company’s stock valued at $19,117,000 after acquiring an additional 193,507 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of Hims & Hers Health by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 1,294,759 shares of the company’s stock worth $11,523,000 after purchasing an additional 22,009 shares during the period. Finally, Mckinley Capital Management LLC boosted its holdings in shares of Hims & Hers Health by 34.9% during the fourth quarter. Mckinley Capital Management LLC now owns 896,020 shares of the company’s stock worth $7,975,000 after purchasing an additional 231,867 shares during the last quarter. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Hims & Hers Health Price Performance

NYSE HIMS traded down $0.51 on Tuesday, reaching $21.20. The company had a trading volume of 5,341,474 shares, compared to its average volume of 7,455,276. Hims & Hers Health, Inc. has a 1 year low of $5.65 and a 1 year high of $25.74. The firm has a 50-day moving average of $21.20 and a 200-day moving average of $15.51. The firm has a market capitalization of $4.55 billion, a PE ratio of -2,120.00 and a beta of 1.08.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, May 6th. The company reported $0.05 earnings per share for the quarter, beating the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million during the quarter, compared to the consensus estimate of $270.37 million. During the same period in the prior year, the firm earned ($0.05) earnings per share. The business’s quarterly revenue was up 45.8% compared to the same quarter last year. As a group, sell-side analysts expect that Hims & Hers Health, Inc. will post 0.2 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms recently weighed in on HIMS. Bank of America increased their target price on Hims & Hers Health from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Thursday, June 13th. Piper Sandler boosted their target price on shares of Hims & Hers Health from $16.00 to $18.00 and gave the company a “neutral” rating in a report on Thursday, July 11th. Seaport Res Ptn reiterated a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They set a “buy” rating and a $20.00 price objective for the company. Finally, Canaccord Genuity Group lifted their target price on Hims & Hers Health from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, May 22nd. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $19.07.

Insider Buying and Selling at Hims & Hers Health

In other Hims & Hers Health news, insider Patrick Harrison Carroll sold 10,000 shares of the firm’s stock in a transaction that occurred on Thursday, May 9th. The stock was sold at an average price of $13.00, for a total transaction of $130,000.00. Following the completion of the sale, the insider now owns 173,880 shares in the company, valued at approximately $2,260,440. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In related news, insider Patrick Harrison Carroll sold 10,000 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $13.00, for a total value of $130,000.00. Following the sale, the insider now directly owns 173,880 shares of the company’s stock, valued at $2,260,440. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Soleil Boughton sold 2,503 shares of the firm’s stock in a transaction on Monday, May 13th. The stock was sold at an average price of $12.33, for a total transaction of $30,861.99. Following the transaction, the insider now directly owns 159,357 shares of the company’s stock, valued at $1,964,871.81. The disclosure for this sale can be found here. Insiders sold a total of 981,485 shares of company stock valued at $18,604,404 in the last ninety days. Insiders own 17.71% of the company’s stock.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.